The European Union has signed a third contract with pharmaceutical companies BioNTech and Pfizer, securing an additional 1.8 billion Covid-19 vaccine doses between the end of 2021 and 2023.

In its statement on Thursday, The European Commission said that the new contract requires that the vaccine production is based in the EU and those essential components are sourced within the bloc. It also stipulates that from the start of the supply in 2022, timely delivery to the European Union is guaranteed. Member states can resell or donate doses to countries in need outside the EU or through the COVAX Facility, contributing to global and fair access to the vaccine across the world, according to the statement.

European Commissioner for Health and Food Safety Stella Kyriakides saud that the EU was prioritizing "technologies that have proven their worth", like mRNA vaccines, but it was keeping its options open.

The EU has already signed contracts with AstraZeneca, Sanofi-GSK, Janssen Pharmaceutica NV, CureVac and Moderna for vaccine supplies. The Commission has granted conditional marketing authorization for the vaccines developed by BioNTech and Pfizer, Moderna, AstraZeneca, as well as Johnson and Johnson.

This diversified portfolio ensures the EU has access to enough doses to immunize its whole population, including for the virus variants, the Commission said in the statement.

Canadian Experts studying effectiveness, safety of COVID vaccines during pregnancy

Turkey introduces 'safe tourism' concept amid COVID-19 pandemic

Portugal declares itself safe to travel with minimum restrictions